Attempts at targeting anti-apoptotic Bcl-xL members in cancers have been primarily focused on inhibiting its anti-apoptotic activity, typically by disrupting its association with pro-apoptotic members and BH3-only proteins to release the sequester of these death-inducing factors and hence to amplify apoptotic signals. Here, BCL2L1 is linked to cancer.